Koninklijke Philips N.V. PHIA
AmsterdamMedical devicesFinancials to Sep 30, 2026 · Updated Nov 11, 2026
Moat ranks
Balance sheet
| €B | Dec '24 | Dec '25 |
|---|---|---|
| Cash | 2.4 | 2.8 |
| Securities | 0.0 | 0.0 |
| Debt | 6.6 | 7.1 |
| Net cash | -4.2 | -4.3 |
| Equity | 12.0 | 11.0 |
- Debt / EBITDA
- 2.60×
- Debt / equity
- 0.65×
- Leases (6/30/26)
- €953M
- Diluted shares
- 990M
- Book value / share
- €11.07
- Price / book
- 2.4×
- Net cash / share
- −€4.37
- Market cap
- €26.5B
- Enterprise value
- €30.8B
Per-share record
Key indicators
| Indicator | Latest | Vs year ago | Last 8 quarters |
|---|---|---|---|
| Revenue growth | 2.1% | +3.8 pts | |
| Operating margin | 3.8% | -3.9 pts | |
| FCF margin | 8.7% | +4.8 pts | |
| Capex / revenue | 3.7% | +0.0 pts | |
| Diagnosis & Treatment comparable sales growth | 0% | -1 pts | |
| Connected Care comparable sales growth | +5% | 0 pts | |
| Personal Health comparable sales growth | +8% | -3 pts | |
| Comparable order intake growth | +8% | 0 pts | |
| Image-guided therapy installed systems · 12/31/25 | ≥20,000 | – | – |
Margins and growth from reported quarters; company KPIs as reported in results releases.
About PHIA
Philips sells diagnostic and interventional equipment, connected monitoring and clinical software, and consumer health devices. Hospital workflow integration and service coverage support repeat business; Enterprise Informatics sits in Connected Care.
- Data Workflow Lockin
Hospitals integrate imaging and interventional equipment with clinical data and procedural workflows.
- Service Field Network
Large installed base supports service contract attachment, uptime guarantees, and upgrade pathways that raise customer switching friction.
- Data Workflow Lockin
Monitoring + enterprise informatics software embed into clinical workflows (alarms, dashboards, documentation), making rip-and-replace costly and risky for hospitals.
- Brand Trust
Trusted consumer brand supports premium shelf/online placement and repeat purchasing in oral care and grooming categories.
- Nov 3, 2026
Respironics reached agreement in principle to resolve DOJ criminal and civil investigations. EUR288m provision recorded, final documentation pending and payment expected Q1 2027. State Attorneys General and other proceedings are excluded. Source: https://www.sec.gov/Archives/edgar/data/313216/000162828026069119/a2026q3-philipsquarterlyen.htm (November 3, 2026).
- Sep 30, 2026 · Legal charge −€288M
Respironics DOJ criminal and civil settlement provision following agreement in principle. Final documentation pending, payment expected Q1 2027; excludes other ongoing proceedings.
- Sep 10, 2026
Philips reported remediation of 99% of actionable sleep-device registrations and 101,000 of 102,000 actionable US ventilator registrations. This reduces recall work, while ventilation remediation and legal investigations remain open.
- Sep 1, 2026
Philips Avent launched its Natural Care Wearable Breast Pump in Western Europe, extending its premium infant-feeding range into a growing wearable category.
- Jul 27, 2026
Philips raised its full-year profit and cash-flow outlook after recognizing a EUR 186 million US tariff refund in Q2. The refund supports cash but does not establish better underlying imaging margins.
Ownership
Go deeper on PHIA
- Compare stock research toolsFundamentals, valuation and screening platforms for PHIA.19 tools
- See PHIA's price chartNo price chart here yet. See price history and indicators.17 tools
- Read PHIA's earnings callsTranscripts and audio of results calls, with management's own words.15 tools
- Investing tool dealsCurrent discounts on research, charting and tracking tools.98 deals
On this page
Financial record
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | Trend | Change 2016–25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Per share (€) | |||||||||||||
| Revenue | 18.76 | 18.81 | 19.00 | 18.42 | 18.89 | 18.08 | 18.73 | 19.16 | 19.31 | 18.53 | 17.94 | -0.1%/yr | |
| Cash flow | 1.26 | 1.98 | 1.87 | 1.95 | 2.74 | 1.72 | -0.18 | 2.25 | 1.68 | 1.22 | 2.52 | -0.4%/yr | |
| Earnings | 0.89 | 1.08 | 1.37 | 1.06 | 1.08 | 0.64 | -1.70 | -0.48 | -0.90 | 0.93 | 0.96 | +0.5%/yr | |
| Free cash flow | 0.45 | 1.07 | 0.98 | 0.93 | 1.76 | 0.91 | -1.03 | 1.57 | 0.96 | 0.52 | 1.85 | +1.8%/yr | |
| Capex | 0.81 | 0.91 | 0.88 | 1.02 | 0.98 | 0.80 | 0.85 | 0.68 | 0.72 | 0.69 | 0.68 | -1.8%/yr | |
| Dividends | 0.36 | 0.41 | 0.42 | 0.49 | 0.00 | 0.51 | 0.43 | 0.00 | 0.00 | 0.34 | 0.36 | -0.5%/yr | |
| Book value | 13.51 | 12.70 | 12.67 | 13.53 | 12.95 | 15.21 | 13.92 | 12.68 | 12.86 | 11.38 | 11.70 | -1.9%/yr | |
| Diluted shares (M) | 929 | 945 | 954 | 931 | 917 | 949 | 952 | 948 | 933 | 963 | 990 | +0.4%/yr | |
| Totals (€B) | |||||||||||||
| Revenue | 17.4 | 17.8 | 18.1 | 17.1 | 17.3 | 17.2 | 17.8 | 18.2 | 18.0 | 17.8 | 17.8 | +0.3%/yr | |
| Operating income | 1.5 | 1.5 | 1.7 | 1.4 | 1.3 | 0.6 | -1.5 | -0.1 | 0.5 | 1.4 | 1.6 | -0.3%/yr | |
| Net income | 0.8 | 1.0 | 1.3 | 1.0 | 1.0 | 0.6 | -1.6 | -0.5 | -0.8 | 0.9 | 1.0 | +0.9%/yr | |
| Free cash flow | 0.4 | 1.0 | 0.9 | 0.9 | 1.6 | 0.9 | -1.0 | 1.5 | 0.9 | 0.5 | 1.8 | +2.2%/yr | |
| Buybacks | 0.6 | 0.6 | 1.0 | 1.4 | 0.3 | 1.6 | 0.2 | 0.7 | 0.4 | 0.0 | 0.1 | – | |
| Dividends | 0.3 | 0.4 | 0.4 | 0.5 | 0.0 | 0.5 | 0.4 | 0.0 | 0.0 | 0.3 | 0.4 | -0.1%/yr | |
| Net cash | -2.9 | -2.5 | -2.8 | -2.6 | -2.5 | -3.5 | -5.9 | -4.7 | -4.2 | -4.3 | -5.4 | −€1.4B | |
| Margins & returns (%) | |||||||||||||
| Gross margin | 45.6 | 46.0 | 47.2 | 46.1 | 45.2 | 41.8 | 40.4 | 41.0 | 43.1 | 45.2 | 46.4 | -0.4 pts | |
| Operating margin | 8.4 | 8.5 | 9.5 | 8.0 | 7.3 | 3.2 | -8.6 | -0.6 | 2.9 | 8.0 | 8.8 | -0.4 pts | |
| Net margin | 4.7 | 5.7 | 7.2 | 5.7 | 5.7 | 3.5 | -9.1 | -2.5 | -4.7 | 5.0 | 5.4 | +0.3 pts | |
| FCF margin | 2.4 | 5.7 | 5.2 | 5.0 | 9.3 | 5.0 | -5.5 | 8.2 | 5.0 | 2.8 | 10.3 | +0.4 pts | |
| ROIC | 8.2 | 9.1 | 10.0 | 7.8 | 7.7 | 2.7 | -6.9 | -0.6 | 2.8 | 8.1 | 8.0 | -0.1 pts | |
| Return on equity | 6.6 | 8.5 | 10.8 | 7.8 | 8.3 | 4.2 | -12.2 | -3.8 | -7.0 | 8.2 | 8.2 | +1.6 pts | |
| R&D % of revenue | 9.6 | 9.9 | 9.7 | 10.4 | 10.5 | 10.5 | 11.7 | 10.4 | 9.7 | 9.5 | 9.7 | -0.0 pts | |
| Stock pay % of revenue | – | 0.7 | 0.5 | 0.6 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | 0.8 | 0.9 | – | |
| Capex % of revenue | 4.3 | 4.8 | 4.7 | 5.5 | 5.2 | 4.4 | 4.5 | 3.5 | 3.8 | 3.7 | 3.8 | -0.6 pts | |
Change uses 2016 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2016 base. Trend shows the fiscal years.
Moat
Moat scorecard
- Strength
- Confidence
- Structure
- Oligopoly
- Durability
- durable
- Trajectory
- stable
- Pricing power
- moderate
- Diagnosis & Treatment49.7%2 claims
- Connected Care28.4%1 claim
- Personal Health21.9%2 claims
Moat claims
- Applies to
- Diagnosis & Treatment
- Confidence
- Durability
- durable
- Trajectory
- stableas of Jun 30, 2026
Hospitals integrate imaging and interventional equipment with clinical data and procedural workflows. Replacing that equipment requires interface validation and staff training. Enterprise Informatics is reported in Connected Care, so its PACS leadership supports the wider platform rather than a separate Diagnosis & Treatment software business.
Long-term imaging partnerships and over 20,000 installed interventional systems support workflow integration. Diagnosis & Treatment comparable sales rose 2% in Q2, but renewal rates are not disclosed.
- Diagnosis & Treatment comparable sales growth0%
- Comparable order intake growth+8%
- Image-guided therapy installed systems≥20,000
- Cloud-native PACS/VNA reducing vendor lock-in
- Open standards (DICOM/HL7/FHIR) improving interoperability
- Hospitals pushing best-of-breed point solutions
- SourcePhilips Capital Markets Day 2026Feb 10, 2026
- SourcePhilips 2026 second-quarter results - enterprise imagingJul 27, 2026
- Applies to
- Diagnosis & Treatment
- Confidence
- Durability
- durable
- Trajectory
- stableas of Jun 30, 2026
Large installed base supports service contract attachment, uptime guarantees, and upgrade pathways that raise customer switching friction.
Over 20,000 interventional systems across more than 80 countries support service coverage, while Q2 imaging sales rose 2%. Service contract retention and attachment rates are not quantified.
- Diagnosis & Treatment comparable sales growth0%
- Comparable order intake growth+8%
- Image-guided therapy installed systems≥20,000
- Growth of third-party servicing (ISOs)
- Service/right-to-repair regulation increasing parts access
- Hospital budget pressure forcing service repricing
- SourcePhilips Capital Markets Day 2026Feb 10, 2026
- SourcePhilips 2026 second-quarter results - Poland deploymentJul 27, 2026
- Applies to
- Connected Care
- Confidence
- Durability
- durable
- Trajectory
- stableas of Jun 30, 2026
Monitoring + enterprise informatics software embed into clinical workflows (alarms, dashboards, documentation), making rip-and-replace costly and risky for hospitals.
Philips serves 90% of the top 100 health systems and continues to win monitoring and imaging partnerships. Q2 Connected Care comparable sales rose 2%; undisclosed renewal rates and Respironics quality risks limit proof of stronger retention.
- Connected Care comparable sales growth+5%
- Comparable order intake growth+8%
- EHR/platform consolidation changing integration dynamics
- Cybersecurity incidents undermining trust
- Regulatory constraints on data sharing/AI
- Respironics investigations and consent-decree execution damaging hospital trust
- SourcePhilips Capital Markets Day 2026Feb 10, 2026
- SourcePhilips 2026 second-quarter results - hospital-at-home monitoringJul 27, 2026
- Applies to
- Personal Health
- Confidence
- Durability
- medium
- Trajectory
- wideningas of Jun 30, 2026
Trusted consumer brand supports premium shelf/online placement and repeat purchasing in oral care and grooming categories.
Personal Health comparable sales rose 8% in Q2 after 8% in 2025, and the company reports three consecutive years of share gains. Premium shaver mix rose five percentage points in 2025, supporting stronger brand demand.
- Personal Health comparable sales growth+8%
- Price competition and private label pressure
- Retailer shelf-space/online ranking shifts
- Negative reviews from quality issues
- SourcePhilips Capital Markets Day 2026Feb 10, 2026
- SourcePhilips 2026 second-quarter results - Personal HealthJul 27, 2026
- Applies to
- Personal Health
- Confidence
- Durability
- medium
- Trajectory
- stableas of Jun 30, 2026
Installed base of devices can drive recurring attachment sales (e.g., blades, heads), improving repeat economics versus one-time device sales.
Philips sells Sonicare brush heads and OneBlade blades through repeat-purchase and subscription offers. Personal Health sales rose 8% in Q2, but the company does not disclose a separate consumable retention or revenue series.
- Personal Health comparable sales growth+8%
- Third-party compatible replacement parts
- Retail substitution toward cheaper accessories
- Consumer backlash against proprietary consumables
- SourcePhilips Capital Markets Day 2026Feb 10, 2026
Profile change log
- Nov 11, 2026 · business change
Respironics reached agreement in principle to resolve DOJ criminal and civil investigations. EUR288m provision recorded, final documentation pending and payment expected Q1 2027. State Attorneys General and other proceedings are excluded. Source: https://www.sec.gov/Archives/edgar/data/313216/000162828026069119/a2026q3-philipsquarterlyen.htm (November 3, 2026).
- Oct 6, 2026 · business change
Philips reported remediation of 99% of actionable sleep-device registrations and 101,000 of 102,000 actionable US ventilator registrations. This reduces recall work, while ventilation remediation and legal investigations remain open.
- Oct 6, 2026 · business change
Philips Avent launched its Natural Care Wearable Breast Pump in Western Europe, extending its premium infant-feeding range into a growing wearable category.
- Oct 6, 2026 · business change
Philips raised its full-year profit and cash-flow outlook after recognizing a EUR 186 million US tariff refund in Q2. The refund supports cash but does not establish better underlying imaging margins.
- Oct 6, 2026 · business change
Philips issued a Trilogy Evo ventilator correction for delivery and alarm problems. The FDA classified it as the most serious recall type, keeping product reliability central to restoring respiratory-care trust.
- Oct 6, 2026 · business change
Philips bought SpectraWAVE for USD 265 million upfront plus contingent consideration, adding coronary intravascular imaging and AI-based physiology tools to its interventional platform.
- Oct 6, 2026 · analyst revision
Imaging workflow evidence now distinguishes equipment integration from Connected Care Enterprise Informatics. All five existing claims have dated trajectories, counterarguments and tests. Consumer brand demand is widening; equipment workflow and consumable protection remain stable.
Industry & peers
Peer map
Hover a point for its values; click a peer to compare. Dashed lines: industry medians.
Global diagnostic imaging and image-guided therapy
Global diagnostic imaging, specialized ultrasound and image-guided procedure systems, with related service, software and enterprise imaging workflows. Excludes general patient monitoring, diagnostic agents and standalone therapeutic radiation systems.
- GE HealthCare
- Siemens Healthineers
- Philips
- Canon
- United Imaging
| Stocks | Moat | Gross m. | Op. m. | |
|---|---|---|---|---|
| PHIA | 77 | 46.4% | 8.8% | |
| Industry median | 14 | 75 | 52.1% | 13.3% |
| Sector median | 55 | 76 | 61.5% | 17.3% |
| All stocks median | 398 | 76 | 53.1% | 20.0% |
Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.
Drivers & risks
- Ageing populations and chronic disease increase diagnostic scans and minimally invasive procedures.
- Hospital staff shortages raise demand for faster scans, remote servicing and integrated clinical workflows.
- AI reconstruction, spectral CT and helium-free MRI can support replacement demand and premium product mix.
- Hospital financing costs and public budgets control the timing of large equipment orders.
- Insurance reimbursement for scans and procedures affects equipment utilization and the cash hospitals can reinvest.
- Hospital tenders and strong GE HealthCare, Siemens, Canon and local competition constrain prices.
- China purchasing delays and preference for domestic equipment can weaken multinational demand.
- Tariffs, currency translation and scarce technical inputs can reduce profit even when comparable demand grows.
- Patient-safety recalls, cybersecurity failures and strict approval rules can delay launches and damage service trust.
- Open data standards and independent service firms reduce the value customers place on a single-vendor software or repair system.
Bulls & bears
Can Philips turn its installed hospital base and consumer demand into lasting profit and cash growth without tariff refunds or renewed recall liabilities?
Arguments
What to watch
- 1Comparable order intake and conversion into Diagnosis & Treatment sales
- 2Segment comparable sales and adjusted EBITA excluding tariff refunds
- 3Service attachment, software renewals and replacement-consumable sales when disclosed
- 4Respironics remediation, investigation outcomes and recall payments
- 5Operating cash flow less gross capex and working-capital outflows
Next check: Read Q4 and FY2026 results when announced, DOJ final settlement documentation and the expected first-quarter 2027 payment; monitor order conversion and consent-decree remediation.
Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.
Free to reuse, commercially too, with a credit link. See the data license.
Moat Score 77/100 by <a href="https://www.findmymoat.com/stocks/XAMS:PHIA">Find My Moat</a> (as of September 2026)Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.